Have a personal or library account? Click to login
The Importance of the Interleukin-8 Study in Chronic Obstructive Pulmonary Disease Cover

The Importance of the Interleukin-8 Study in Chronic Obstructive Pulmonary Disease

Open Access
|Oct 2023

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report.
  2. Ghidul ENSP pentru tratamentul dependen ei de tutun. European Network for Smoking and Tobacco Prevention. 2019.
  3. Ulmeanu R, Fildan AP, Oancea C, Mihăl an F. Recomandări de diagnostic și tratament în bronhopneumopatia obstructivă cronică. Editura Medicală, București. 2019. p 15-16.
  4. Bălă GP, Râjnoveanu RM, Tudorache E, et al. Air pollution exposure- the (in)visible risk factor for respiratory disease. Environ Sci Pollut Res Int. 2021; 28(16): 19615-19628.
  5. Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: Impact, measurement and mechanisms. Respirology. 2015; 20(8):1160-71.
  6. Hlapcic I, Belamaric D, Bosnar M, et al. Combination of Systemic Inflammatory Biomarkers in Assessment of Chronic Obstructive Pulmonary Disease: Diagnostic Performance and Identification of Networks and Clusters. Diagnostics (Basel). 2020; 10(12): 1029.
  7. Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018; 13:3341-3348.
  8. Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther. 2019; 198:160-188.
  9. Córdoba-Lanús E, Baz-Dávila R, Espinoza-Jiménez A, et al. IL-8 gene variants are associated with lung function decline and multidimensional BODE index in COPD patients but not with disease susceptibility: a validation study. COPD. 2015; 12(1):55-61.
  10. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 2010; 7(3):e1000220.
  11. Che L, Yu C, Chen G, et al. The Inflammatory Response Induced by RELMβ Upregulates IL-8 and IL-1β Expression in Bronchial Epithelial Cells in COPD. Int J Chron Obstruct Pulmon Dis. 2021; 16:2503-2513.
  12. Oishi K, Matsunaga K, Shirai T, et al. Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease. J Clin Med. 2020; 9(8):2670.
  13. De Llano LP, Cosío BG, Iglesias A, et al. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach. Int J Chron Obstruct Pulmon Dis. 2018; 13:591-601.
  14. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017; 195(5):557–82.
  15. Perera WR, Hurst JR, Wilkinson TMA, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29(3): 527–34.
  16. Perotin JM, Dury S, Renois F, et al. Detection of multiple viral and bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a pilot prospective study. J Med Virol. 2013; 85(5): 866–73.
  17. Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Chest Med. 2020; 41(3):421-438.
  18. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000; 55: 114–120.
  19. Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types. Front. Physiol. 2018; 9:113.
  20. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59(7):574-80.
  21. Katsiki N, Stoian AP, Steiropoulos P, et al. Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. Metabolites. 2020; 10(11):465.
  22. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013; 107: 1376–1384.
  23. Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014; 69: 718–723.
  24. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018; 27(149):180057.
  25. Zhou JS, Li ZY, Xu XC, et al. Cigarette smoke-initiated autoimmunity facilitates sensitisation to elastin-induced COPD-like pathologies in mice. Eur Respir J. 2020; 56(3):2000404.
  26. Andreeva E, Pokhasnikova M, Lebedev A, et al. Inflammatory parameters and pulmonary biomarkers in smokers with and without chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2021; 13(8):4812-4829.
  27. Gao J, Zhan B. The effects of Ang-1, IL-8 and TGF-β1 on the pathogenesis of COPD. Mol Med Rep. 2012; 6(5):1155-9.
  28. Gea J, Pascual S, Casadevall C, et al. Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings. J Thorac Dis. 2015; 7(10):E418-38.
  29. Crul T, Spruit MA, Gayan-Ramirez G, et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest. 2007; 37(11):897-904.
  30. Henrot P, Dupin I, Schilfarth P, et al. Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting. Int J Mol Sci. 2023; 24(7):6454.
  31. Akpınar EE, Akpınar S, Ertek S, et al. Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk Toraks. 2012; 60(3):230-7.
  32. Minas M, Kostikas K, Papaioannou AI, et al. The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without co-morbidities. COPD. 2011; 8(6):414-20.
  33. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011; 121(6):2094-101.
  34. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009; 136(4):1039-1046.
  35. Passey SL, Hansen MJ, Bozinovski S, et al. Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease. Pharmacol Ther. 2016; 166:56-70.
  36. Trøseid M, Lappegård KT, Claudi T, et al. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J. 2004; 25(4):349-55.
  37. De Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008; 582(1):97-105.
  38. Gerhardt CC, Romero IA, Cancello R et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol. 2001; 175:81–92.
  39. Sarir H, Mortaz E, Karimi K, et al. Cigarette smoke regulates the expression of TLR4 and IL-8 production by human macrophages. J Inflamm (Lond). 2009; 6:12.
  40. Kotlyarov S. High-Density Lipoproteins: A Role in Inflammation in COPD. Int J Mol Sci. 2022; 23(15):8128.
DOI: https://doi.org/10.2478/inmed-2023-0255 | Journal eISSN: 1220-5818 | Journal ISSN: 1220-5818
Language: English
Page range: 19 - 25
Published on: Oct 20, 2023
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2023 Elena-Andreea Moaleș, Adriana Chetran, Ioana Mădălina Zota, Corina Dima Cozma, Florin Mitu, published by Romanian Society of Internal Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.